Genotype and Lifetime Burden of Disease in Hypertrophic CardiomyopathyCarolyn Y. Ho, Sharlene M. Day, Euan A. Ashley et al.|Circulation|2018Cited by 837
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus documentMarieke Biegstraaten, Carla E. M. Hollak, Reynir Arngrı́msson et al.|Orphanet Journal of Rare Diseases|2015Cited by 345
International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)Constantinos O’Mahony, Perry Elliott, Iacopo Olivotto et al.|Circulation|2017Cited by 209
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitorsAndrea Boutros, Enrica T. Tanda, Roberta Carosio et al.|Immuno-Oncology Technology|2023Cited by 9